The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.
 
Stephanie Lheureux
Honoraria - AstraZeneca; GlaxoSmithKline; Merck; Roche/Genentech; Seagen; Shattuck Labs
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Merck; Novartis; Roche/Genentech; Shattuck Labs
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Tesaro (Inst)
 
Taymaa May
Honoraria - AstraZeneca; GlaxoSmithKline
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
 
Michelle K. Wilson
Research Funding - Foundation Medicine (Inst)
 
Diane M. Provencher
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Abbvie; AstraZeneca
 
Susie Lau
No Relationships to Disclose
 
Prafull Ghatage
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Merck
 
Johanne I Weberpals
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
 
Susana N. Banerjee
Stock and Other Ownership Interests - Perci Health
Honoraria - AstraZeneca; GlaxoSmithKline; Immunogen; Mersana; MSD Oncology; Novocure; Roche; Takeda; Verastem
Consulting or Advisory Role - Astrazeneca; Epsilogen; GlaxoSmithKline; Immunogen; Mersana; MSD Oncology; Myriad Genetics; Novartis; OncXerna Therapeutics; Regeneron; Seagen; Shattuck Labs; Verastem (I); Zymeworks
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Verastem
(OPTIONAL) Uncompensated Relationships - ESMO
 
Iain A. McNeish
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; OncoC4; Roche; Theolytics; Transgene
Consulting or Advisory Role - AstraZeneca; BeiGene; Carrick Therapeutics; Clovis Oncology; Epsila Bio; GlaxoSmithKline; Roche; Scancell Ltd.
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Neesha C. Dhani
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Knight Therapeutics; Merck
 
Sarah Ferguson
No Relationships to Disclose
 
Genevieve Bouchard-Fortier
No Relationships to Disclose
 
Trevor John Pugh
Honoraria - AstraZeneca; Illumina; Merck; PACT Pharma
Consulting or Advisory Role - Axiom Healthcare Strategies; Chrysalis Biomedical Advisors; SAGA Diagnostics
Research Funding - Roche
Patents, Royalties, Other Intellectual Property - Hybrid-capture sequencing for dete rmining immune cell clonality
 
Xiang Y Ye
No Relationships to Disclose
 
Sarah Garisto
No Relationships to Disclose
 
Judy Quintos
No Relationships to Disclose
 
Janelle Ramsahai
No Relationships to Disclose
 
Horace Wong
No Relationships to Disclose
 
Valerie Bowering
No Relationships to Disclose
 
Amit M. Oza
Consulting or Advisory Role - AstraZeneca; MorphoSys
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Ozmosis Research